FDA approves second Alzheimer’s drug that can modestly slow disease

The FDA has approved the use of Kisunla, known chemically as donanemab, for use in mild or early cases of dementia caused by Alzheimer’s (Yui Mok/PA)

US officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.

The Food and Drug Administration (FDA) approved Eli Lilly’s Kisunla, known chemically as donanemab, for mild or early cases of dementia caused by Alzheimer’s.